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Are phase 0 clinical trials really necessary? 
This question was posed by James Doroshow (National Cancer 
Institute, Bethesda, USA) at the 20th EORT-NCI-AARC 
Symposium on Molecular Targets and Cancer Therapeutics 
(Geneva, 21–24 October 2008). Together with E Leo (Beerse, 
Belgium), James Doroshow—since 2004 Director of the Division 
of Cancer Treatment and Diagnosis at NCI—was co-chairing 
the workshop on phase 0 clinical trials. In his introduction to the 
speakers, Doroshow raised six open questions, namely whether 
phase 0 trials are useful, ethically acceptable, feasible, whether 
they speed up the drug development process and save money, 
and whether there is room for improvement. 
In the Critical Path Report published in March 2004, the US 
Food and Drug Administration denounced the ‘slowdown, 
instead of expected acceleration, in innovative medical 
therapies reaching patients’ [1]. Following this concept, in 
January 2006, the FDA published new industry guidelines for 
early exploratory drug studies (i.e. phase 0 studies) in humans 
[2]. 
In 2003, the European Agency for the Evaluation of Medicinal 
Products (EMEA) had issued a similar concept note, followed by 
a Position Paper on the non-clinical safety studies needed to 
support human clinical trials, using microdosing techniques [3]. 
As defined by EMEA and FDA guidelines, phase 0 trials are 
early first-in-human clinical studies, conducted before the 
traditional dose escalation, safety and tolerance phase 1 
studies. 
According to both regulatory agencies, phase 0 trials are 
necessary, since current strategies for drug development are 
still predominantly based on the assumption that the 
investigational agent has a dose–toxicity relationship, and that 
efficacy is somewhat related to toxicity, but such assumptions 
may not be valid for new molecularly targeted agents [4]. For 
such new drugs, there is need to alter the traditional drug-
development sequence, where exploratory phase 0 trials should 
be designed that focus on extensive agent characterization and 
target-assay development, including molecular imaging studies, 
in a limited number of patients (10–15), who will each be 
exposed to a limited number of doses of the study agent (less 
than two weeks) [2,3]. 
Phase 0 trials have no therapeutic intent and, at least in 
principle, should eliminate therapeutic failures early in the 
cancer drug development for agents without biological 
effectiveness, thus reducing costs and time of drug 
development [4,5]. 
According to C Garner (Xceleron Ltd, Heslington York, UK) 
humans are ‘the best model for humans’, and the excessive 
weight put on animal models for cancer drug development must 
be shifted in the direction of phase 0 trials. ‘The poor correlation 
between animal and human bioavailability’, Garner said, can be 
represented in a chart that ‘looks like stars in the sky’. Instead of 
using animals for cancer drug modelling, ‘you may as well toss 
a coin’, he also added provocatively [6]. Garner then dwelled on 
the technical details of AMS (accelerator mass spectrometry) as 
a tool for phase 0 microdose studies to understand human 
anatomy and drug bioavailability [7,8]. Microdose studies are 
one of the major applications of phase 0 trials, as illustrated by 
FDA and EMA guidelines [2,3], which define a microdose as 
less than 1/100th of the dose of the test substance calculated 
from  in vitro and animal models to yield a pharmacological 
effect, with a maximum dose ≤ 100 μg [3]. AMS separates C 
isotopes on the basis of mass and energy differences and 
allows the study of the metabolic pathways of a 14C labelled 
drug and its metabolites. 
Because of the AMS huge scale sensitivity, up to 10-18 -10-21 
g, the radiation hazard for the patient becomes negligible. As a 
consequence, clinical studies with AMS do not require extensive 
pre-clinical animal toxicology work. This trend is in line with the 
FDA and EMEA guidelines, which for microdose studies require 
only extended single-dose toxicity studies in both genders of a 
single mammalian species to establish a dose inducing a 
minimal toxic effect or a safety margin [2,3]. In conclusion, 
Garner remarked how phase 0 microdose studies are definitely 
useful for providing early information about human absorption, 
distribution, metabolism and excretion (ADME) data; for 
comparing ADME parameters for several drug candidates and 
choosing the lead molecule to take on and develop, and for 
assisting in selecting the first dose for a subsequent phase 1 
study. In his experience, phase 0 studies have a short, six-
month timeframe from the bench to the bedside and do speed 
up the drug development process while helping to determine the 
approximate cost of the drug [6]. One obstacle may be 
represented by the pharmacokinetic profile of the drug, as a 
microdose may not predict the behaviour of clinical doses if 
there is no linear PK. Drugs with a linear or near linear PK—
which constitute about 70% of the totality of the candidates 
according to Garner [6]—should be chosen as candidates for 
phase 0 studies. 
‘Change we need’ was Jeremy Collins’ (National Cancer 
Institute, Rockville, MD, USA) opinion on the cancer drug 
development process and the US political situation. The phase 
0 concept is ‘not simply a small incremental change in the 
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cancer drug development process’, but is a drastic ‘re-
engineering of the drug pipeline’ [9]. According to Collins, phase 
0 cancer trials require a role reversal in goal priority, as cancer 
trials until the 1990s had as primary goal toxicity determination, 
and as secondary activity determination, while phase 0 studies 
have as primary goal pharmacodynamics assessment (as 
occupancy of the receptor by the compound, determination of 
the inhibition of the target), as secondary pharmacokinetics (as 
the extent of absorption of half life of the drug in the body), and 
toxicity is not expected [10]. In his talk, Collins focused on the 
applications of phase 0 trial for establishing in humans a 
‘molecular proof of concept’, which include an evaluation of the 
biological effects on the target in tumour biopsies or other 
surrogates (such as peripheral blood mononuclear cells) and a 
determination of the PD and PK of the drug. In such 
applications, a pharmacological concentration of the drug can 
be (briefly) achieved. Collins also mentioned the importance of 
imaging studies to have a functional relevance and not be 
merely ‘decorations’ to a study, [11] as they should inform on 
the reception and/or compound biodistribution. To be useful, 
phase 0 trials must be able to answer fundamentally important 
‘stop/go’ questions, such as: Does the drug hit the target? 
The raising of such questions necessitates a redesign of the 
information flow in the drug development process in order to 
find a different proof of concept to facilitate decision making. As 
an example, Collins talked about the first NCI phase 0 trial with 
the PARP inhibitor (ABT-888) done in collaboration with Abbott 
industries, where two fundamentally stop/go questions were 
answered positively, thus permitting the continuation of the drug 
development: Can the target plasma concentration be achieved 
orally? And can tumour biopsies give definitive results with a 
single dose [12,13]? The requirement of multiple biopsies for 
patients in trials with no direct benefits is ethically problematic, 
as remarked by a discussion that followed Collins’ speech, and 
valid alternatives are actively searched for, such as imaging, 
peripheral blood mononuclear cells and circulating tumour cells. 
Phase 0 cancer trials are unique in having no therapeutic intent 
at all, and the ethical solution will probably not look like a wide 
comprehensive blanket covering all trials of this kind, but as a 
case-by-case justification. 
G Gordon (Abbott Oncology Development, USA) gave his 
industry perspective to the experience of the first phase 0 trial 
conducted together with the NCI on the ABT-888 molecule [13], 
where information from the phase 0 study provided 
informational guidance for subsequent phase 1 combination 
trials with FDA-approved chemotherapeutic agents. A research 
performed on the FDA clinical trials website found eight phase 1 
ABT-888 combination trials, six of which currently recruiting, 
spanning from glioblastoma therapy to non-Hodgkin lymphoma 
to CML, and to solid tumours such as breast and ovarian 
cancer, and melanoma [14]. Gordon and Collins therefore 
agreed that the primary goal of a phase 0 trial must be the 
evaluation of target modulation, which has to inform decision 
making for further drug developments and for pipeline 
prioritization decisions. Two different requirements are both 
fundamentally important in this respect, as Gordon 
underscored: (1) the choice of a good drug candidate for a 
phase 0 trial, as not all agents are suitable candidate drugs [15], 
(2) the willingness to stop the drug under scrutiny if there are no 
definitive answer to the questions raised. Only if both 
requirements are satisfied will phase 0 cancer trials fulfil their 
expectations to speed up the drug development process and to 
cut costs. 
A European perspective on the nascent field was given by JHM 
Schellens (The Netherlands Cancer Institute, Amsterdam), who 
explained how the EMEA guidelines provide flexible guidelines 
for phase 0 trials and touched upon the issue of feasibility [2]. 
Interestingly, while FDA’s guidance does not issue new 
regulation, but is an interpretation of existing recommendations 
on drug development—stressing how limited, early first-in-
human studies are often supported by a more extensive pre-
clinical database than required by regulation—the EMA Position 
paper talks about a new kind of non-clinical safety studies 
needed to support human clinical trials with a single dose of a 
pharmacologically active compound [16]. Shellens provided 
examples of drugs for which a phase 0 approach would have 
worked, had the guidelines been there a few years ago. A good 
example of a phase 0 candidate was EO9, a bioreductive agent 
with an excellent pre-clinical in vivo activity [17], or SPI-77, a 
formulation of cisplatin within a liposome [18]. According to 
Schellens, phase 0 studies are not entirely new (for a similar 
opinion read [19]), and in support of his claim, he quoted a 1994 
study with capecitabine where, prior to the phase 1 trial, a PK 
comparison was made between two almost identical chemical 
structures in a clinical ADME study [20]. Schellens concluded 
his speech with some critical remarks and challenges to 
feasibility that must be kept in mind when planning a phase 0 
trial, among others: the presence or not of a linear 
pharmacokinetic for the drug, the availability of a sensitive 
bioanalytical method and of a sufficiently qualified research 
team and adequate infrastructure, the careful examination of the 
drug candidates, the availability of a measurable PD effect at 
very low doses, the feasibility of tumour tissue sampling with 
related ethical considerations, the choice of good patient 
candidates. ‘Phase 0 will not solve all our problems’, Schellens 
argued, ‘but they can solve some of our problems, as they can 
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help identify optimal clinical candidate among a series of similar 
agents and may save time and money’. But, he emphasized, 
‘phase 0 trials will not solve any problem if there is a lack of pre-
clinical proof of principle of the drug mechanism of action, or if a 
good biomarker is absent, or if the PK is very complex or the 
linearity of the PD is not established’ [16]. 
At the end of the day, the phrase ‘phase 0 trials’ looks like a big 
umbrella covering maybe too many things: Microdose studies, 
functional imaging studies, molecular proof-of-concept studies, 
which briefly reach a pharmaceutical dose. Is there room for 
improvement in the current drug pipeline, for example in the 
incorporation of phase 0 trials in a phase 1 studies, as
Schellens proposed, or only for a drastic re-engineering of the 
drug development process, as Collins argued? 
Wouldn’t it be more appropriate to call phase 0 trials only those 
studies where no pharmaceutical therapeutic dose is ever 
reached, as microdose studies and imaging trials, for which pre-
clinical animal studies requisites would remain very low, and the 
risk of toxicity too? And how many research centres in the world 
would actually meet the high standards required to perform a 
phase 0 trial? 
It is still too early to provide such answers. Only in a few years 
we will be able to respond to these issues, and to the initial 
point posed by James Doroshow, whether phase 0 trials are 
really necessary. Most importantly, we should not give for 
granted the participation of the patients in trials where no direct 
benefit is expected, and who would be motivated only by an out-
of-the-ordinary altruism. 
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